Bellevue Group AG decreased its position in C.R. Bard, Inc. (NYSE:BCR) by 5.2% during the first quarter, Holdings Channel reports. The firm owned 48,430 shares of the medical instruments supplier’s stock after selling 2,670 shares during the period. C.R. Bard makes up 1.6% of Bellevue Group AG’s holdings, making the stock its 20th largest position. Bellevue Group AG’s holdings in C.R. Bard were worth $12,037,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Global Financial Private Capital LLC acquired a new position in shares of C.R. Bard during the first quarter worth $252,000. Marietta Investment Partners LLC acquired a new position in shares of C.R. Bard during the first quarter worth $885,000. Bridgewater Associates LP acquired a new position in shares of C.R. Bard during the first quarter worth $985,000. TIAA CREF Investment Management LLC boosted its position in shares of C.R. Bard by 21.0% in the first quarter. TIAA CREF Investment Management LLC now owns 316,266 shares of the medical instruments supplier’s stock worth $78,605,000 after buying an additional 54,940 shares during the period. Finally, Teachers Advisors LLC boosted its position in shares of C.R. Bard by 5.7% in the first quarter. Teachers Advisors LLC now owns 142,186 shares of the medical instruments supplier’s stock worth $35,339,000 after buying an additional 7,705 shares during the period. 88.04% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Shares of C.R. Bard, Inc. (BCR) traded up 0.22% during trading on Tuesday, hitting $315.89. 132,509 shares of the company’s stock were exchanged. The firm has a market capitalization of $22.88 billion, a PE ratio of 40.20 and a beta of 0.64. The stock’s 50 day moving average is $309.70 and its 200 day moving average is $258.71. C.R. Bard, Inc. has a 1-year low of $203.63 and a 1-year high of $316.22.

C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.65 by $0.22. The firm had revenue of $938.80 million for the quarter, compared to analyst estimates of $916.15 million. C.R. Bard had a net margin of 15.70% and a return on equity of 48.72%. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.34 EPS. On average, equities research analysts forecast that C.R. Bard, Inc. will post $11.78 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 4th. Shareholders of record on Monday, July 24th will be paid a $0.26 dividend. The ex-dividend date of this dividend is Thursday, July 20th. This represents a $1.04 annualized dividend and a yield of 0.33%. C.R. Bard’s dividend payout ratio is presently 13.21%.

ILLEGAL ACTIVITY NOTICE: “Bellevue Group AG Decreases Stake in C.R. Bard, Inc. (BCR)” was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/06/20/bellevue-group-ag-decreases-stake-in-c-r-bard-inc-bcr.html.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective for the company in a research note on Tuesday, June 13th. Raymond James Financial, Inc. cut shares of C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a research note on Wednesday, April 26th. Wells Fargo & Co cut shares of C.R. Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. BMO Capital Markets cut shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price objective for the company. in a research note on Tuesday, April 25th. Finally, Morgan Stanley cut shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $265.62.

In other C.R. Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of the company’s stock in a transaction that occurred on Monday, April 24th. The shares were sold at an average price of $304.00, for a total value of $1,101,088.00. Following the transaction, the vice president now owns 10,139 shares in the company, valued at approximately $3,082,256. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.80% of the stock is currently owned by corporate insiders.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.